Publications by authors named "Soumya D Chakravarty"

Claim this Profile
I
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study.
Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Soumya D Chakravarty

Ann Rheum Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors.
Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Elizabeth Adamson

Rheumatol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors.
Philip J Mease, Jessica A Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Elizabeth Adamson

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.
Herta Crauwels, Sarah Ringold, Samantha Howard, Bart Van Hartingsveldt, Valerie Smith, Soumya D Chakravarty

Paediatr Drugs· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.
Alexis Ogdie, Soumya M Reddy, Sarah H Gillespie, M Elaine Husni, Jose U Scher, Soumya D Chakravarty

Trials· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.
Philip J Mease, Shannon A Ferrante, Natalie J Shiff, Timothy P Fitzgerald, Soumya D Chakravarty

Adv Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study.
Philip J Mease, Xenofon Baraliakos, Vinod Chandran, Enrique R Soriano, Peter Nash, Soumya D Chakravarty

ACR Open Rheumatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial.
Stefan Siebert, Georg Schett, Siba P Raychaudhuri, Monica Guma, Warner Chen, Soumya D Chakravarty

Ther Adv Musculoskelet Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors.
Jessica A Walsh, Iris Lin, Ruizhi Zhao, Natalie J Shiff, Laura Morrison, Soumya D Chakravarty

Drugs Real World Outcomes· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
Christopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, John Tesser, Soumya D Chakravarty

Clin Rheumatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
Stefan Siebert, Laura C Coates, Georg Schett, Siba P Raychaudhuri, Warner Chen, Soumya D Chakravarty

Arthritis Rheumatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty

ACR Open Rheumatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
Alexis Ogdie, Joseph F Merola, Philip J Mease, Christopher T Ritchlin, Jose U Scher, Soumya D Chakravarty

BMC Rheumatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation.
Rachael A Gordon, Yann Nguyen, Nathan Foulquier, Maxime Beydon, Tamer A Gheita, Soumya D Chakravarty

Semin Arthritis Rheum· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies.
Xenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, Cinty Gong, May Shawi

Rheumatol Adv Pract· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies.
Joseph F Merola, Soumya D Chakravarty, Olivia Choi, Daphne Chan, Alice B Gottlieb

J Am Acad Dermatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study.
Laura C Coates, Proton Rahman, Philip J Mease, May Shawi, Emmanouil Rampakakis, Soumya D Chakravarty

BMC Rheumatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
Philip J Mease, Alice B Gottlieb, Alexis Ogdie, Iain B McInnes, Soumya D Chakravarty

Clin Rheumatol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Bruce Strober, Laura C Coates, Mark G Lebwohl, Atul Deodhar, Evan Leibowitz, Soumya D Chakravarty

Drug Saf· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Iris Lin, Soumya D Chakravarty

Rheumatol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.
Philip J Mease, Dafna D Gladman, Denis Poddubnyy, Soumya D Chakravarty, May Shawi

Rheumatol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
Ana-Maria Orbai, Soumya D Chakravarty, Yin You, May Shawi, Ya-Wen Yang

Dermatol Ther (Heidelb)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
Georg Schett, Warner Chen, Sheng Gao, Soumya D Chakravarty, May Shawi

Arthritis Res Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
Georg Schett, Warner Chen, Sheng Gao, Soumya D Chakravarty, May Shawi

Arthritis Res Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study.
Laure Gossec, Elke Theander, Soumya D Chakravarty, Paul Bergmans, Frederic Lavie

Arthritis Res Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis